STE
Strong BuyPremium GrowerAI pickSTERIS plc · Healthcare · United States · $22.6B cap · $166.4M/day traded
$232.15 -0.0% · close 23 Oct · scored 24 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 24 Oct 2026, MoatMap's StockRank for STERIS plc (STE) is 83/100, ranked against 24,000+ stocks in 35 markets (Quality 69, Value 47, Momentum 65, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
STERIS supplies sterilisation equipment, consumables and outsourced sterilisation services to hospitals, drug makers and medical device makers. Much of its revenue is recurring (consumables, service contracts and contract sterilisation), the work is regulated and hard to switch, and demand grows with procedure volumes rather than the economy. The company is investing about $600 million in a new North Carolina manufacturing campus and is buying back shares (about 0.5% of shares in the last 90 days), which points to management confidence in long-run demand. In a period where rates stay high, a business with steady cash flow and little exposure to energy or food prices has an advantage over more cyclical or leveraged companies.
ABOUT STERIS PLC
Read
STERIS plc is a global provider of infection prevention and other procedural products and services for healthcare, pharmaceutical, and research customers. Its competitive moat is built on its comprehensive portfolio of sterilization equipment, consumables, and services, strong regulatory compliance expertise, and established relationships within the healthcare sector, making it a market leader in infection control.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.2B | 4.5B | 5.1B | 5.5B | 5.9B | 8.9% | 6.0B | 6.4B | 6.8B | 7.1% |
| EPS | 2.50 | 1.07 | 3.83 | 6.24 | 7.97 | 33.6% | 8.18 | 8.77 | 9.66 | 10.1% |
| Shares | 100.1M | 98.6M | 98.9M | 98.3M | 97.8M | -2.3% | 97.5M | — | — | — |
| Debt | 3.3B | 3.2B | 3.4B | 2.2B | 2.1B | -10.7% | 2.0B | — | — | — |
| Equity | 6.5B | 6.1B | 6.3B | 6.6B | 7.2B | 2.4% | — | — | — | — |
| Op CF | 684.8M | 756.9M | 973.3M | 1.1B | 1.3B | 18.3% | 1.3B | — | — | — |
| Inv CF | -666.6M | -383.3M | -887.4M | 388.8M | -512.5M | — | — | — | — | — |
| Fin CF | 115.8M | -498.7M | -85.2M | -1.6B | -568.2M | — | — | — | — | — |
No new 52-week low for 23 weeks, 20% above that low, but not back above a rising 50-day average.
The Momentum score still reads 65: it looks back six months, so it has not caught up with this fall.
Calmer than 81% of stocks we rank over the past year (26% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STE | STERIS plc(you) | $22.6B | 83 | Strong Buy |
| DXCM | DexCom, Inc. | $29.4B | 81 | Strong Buy |
| ZBH | Zimmer Biomet Holdings, Inc. | $18.8B | 88 | Strong Buy |
| GEHC | GE HealthCare Technologies Inc. | $32.3B | 73 | Buy |
| GMED | Globus Medical, Inc. | $10.9B | 89 | Strong Buy |
| BIO-B | Bio-Rad Laboratories, Inc. | $8.3B | 76 | Buy |
| EW | Edwards Lifesciences Corporation | $51.3B | 71 | Buy |
| HAE | Haemonetics Corporation | $5.4B | 84 | Strong Buy |
| PEN | Penumbra, Inc. | $12.8B | 55 | Hold |
| PODD | Insulet Corporation | $10.3B | 59 | Hold |
Peer medians: ROE -31.5% · P/E 27.3x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.